July 2026: Biotech & Pharma NEWS Roundup

Welcome to your essential overview of the global biotech and pharmaceutical landscape for June 2026!

This month was dominated by AI cementing itself as a core part of drug discovery, with partnerships spanning Anthropic, NVIDIA, Insilico Medicine, and major pharmaceutical companies. At the same time, billion-dollar licensing deals and acquisitions showed that large pharma is aggressively buying innovation rather than building everything internally, particularly in obesity, oncology, radiopharmaceuticals, and gene editing. Regulatory headlines—from the FTC's lawsuit against Hims & Hers to renewed debates around animal testing—reminded us that policy is evolving just as quickly as the science. And with companies like Apnimed and Scribe Therapeutics successfully entering the public markets, investor confidence appears to be returning to biotech. The takeaway is clear: the future of healthcare will be shaped by the convergence of biology, artificial intelligence, precision medicine, and strategic dealmaking—and this month may be remembered as another major step toward that future.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #BiotechNews #PharmaNews

Transcript

Hello and welcome to Petri Dish Perspectives, the podcast where we geek out about science and the companies shaping the future of healthcare. I’m your host, Manead, and I’m a PhD scientist by training, and a storyteller by choice. 

Due to continued demand, I’m reporting monthly episodes for biotech and pharma news. Each monthly recap for news is released on the first day of every month and my goal is to deliver digestible pieces of news on pharma and biotech companies in under 15 mins.

Grab your coffee or tea cuz you’re in for a treat! 

🤖 AI & Partnerships

Anthropic launches life sciences-focused Claude model (https://www.cnbc.com/2026/06/30/anthropic-launches-ai-drug-discovery-program-claude-science.html) 

Anthropic officially entered the life sciences race with the launch of Claude for Life Sciences, an AI model optimized for pharmaceutical research, biological reasoning, literature analysis, and scientific workflows. While OpenAI, Google DeepMind, and Microsoft have been expanding into healthcare, Anthropic is positioning itself as an enterprise AI partner for pharmaceutical R&D. The bigger trend here is that AI is rapidly moving beyond writing emails and generating code—it is becoming an everyday research assistant capable of helping scientists interpret papers, generate hypotheses, design experiments, and navigate enormous biological datasets. Expect virtually every large pharmaceutical company to evaluate specialized large language models over the next few years.

Takeda partners with Insilico Medicine in a $600 million deal (https://www.wsj.com/tech/biotech/takeda-insilico-strike-ai-drug-discovery-deal-worth-up-to-600-million-e0891df)

Takeda expanded its AI strategy by signing a discovery partnership with Insilico Medicine, one of the pioneers of generative AI for drug discovery. Rather than relying solely on traditional high-throughput screening, the companies hope to use machine learning to identify novel therapeutic targets and design molecules more efficiently. This deal reinforces a growing industry trend: pharmaceutical companies increasingly view AI not as a replacement for scientists but as a tool that can dramatically shorten the earliest stages of drug discovery, where identifying viable drug candidates has historically taken years.

Bristol Myers Squibb partners with NVIDIA (https://www.fiercebiotech.com/biotech/bms-expands-ai-footprint-nvidia-create-largest-drug-rd-supercomputer) 

Bristol Myers Squibb announced a strategic collaboration with NVIDIA to accelerate AI-powered drug discovery, digital biology, and computational chemistry. NVIDIA's accelerated computing infrastructure is becoming one of the industry's preferred platforms for running molecular simulations, protein modeling, and large-scale biological datasets. Rather than simply purchasing GPUs, pharmaceutical companies are now embedding AI directly into R&D workflows, suggesting the future of medicine will increasingly be designed in silico before entering the laboratory.

Eli Lilly partners with Oura (https://ouraring.com/blog/lilly-equity-investment/?srsltid=AfmBOopmWdKVSHk0xKqcS5KB8m_sy1TpMqgJPTi4wCbixZvpkBW7Rwo2)

Eli Lilly announced a collaboration with wearable technology company Oura, maker of the popular smart ring. The partnership aims to better understand how wearable physiological data—including sleep, activity, heart rate variability, and recovery—can support obesity management and other chronic diseases. As GLP-1 therapies reshape healthcare, pharmaceutical companies are increasingly looking beyond the drug itself and toward comprehensive digital ecosystems that improve long-term patient outcomes.

💰 Mergers, Acquisitions & Licensing

AstraZeneca licenses kidney disease therapy from CSPC for $1.7 billion pact (https://www.fiercebiotech.com/biotech/astrazeneca-pays-go-chinese-partner-cspc-30m-form-kidney-drug-discovery-pact)

AstraZeneca signed a licensing agreement worth up to $1.7 billion with China's CSPC Pharmaceutical for a preclinical therapy targeting chronic kidney disease. The agreement reflects a broader trend in which large multinational pharmaceutical companies increasingly source innovative assets from Chinese biotech firms. Over the last several years, China has evolved from primarily producing generic medicines into one of the world's fastest-growing innovation hubs for novel therapeutics.

Novartis acquires rights to Myricx ADC programs for $1.1 billion (https://www.fiercebiotech.com/biotech/novartis-pay-11b-upfront-myricx-expand-adc-pipeline)

Novartis strengthened its oncology pipeline through a licensing deal worth up to $1.1 billion with UK-based Myricx Bio. The agreement focuses on antibody-drug conjugates, or ADCs, one of oncology's hottest therapeutic modalities. Following the success of Enhertu and other ADCs, virtually every major pharmaceutical company is racing to build next-generation targeted cancer therapies capable of delivering highly potent drugs directly into tumor cells while minimizing systemic toxicity.

Vertex acquires Crinetics for roughly $10 billion (https://news.vrtx.com/news-releases/news-release-details/vertex-acquire-crinetics-pharmaceuticals)

Vertex Pharmaceuticals announced plans to acquire Crinetics Pharmaceuticals, significantly expanding its endocrine disease portfolio. While Vertex built its reputation transforming cystic fibrosis, the company has increasingly diversified into pain management, kidney disease, diabetes, and endocrine disorders. The acquisition highlights Vertex's strategy of leveraging its substantial cash flows from CF to become a broader specialty pharmaceutical leader.

AstraZeneca expands obesity ambitions with Zegfrovy (https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-licenses-novel-egfr-inhibitor.html)

AstraZeneca committed another $1.5 billion to strengthen its obesity pipeline through a licensing agreement involving Zegfrovy. Like nearly every large pharmaceutical company today, AstraZeneca is racing to establish a competitive position in the rapidly expanding obesity market, which many analysts believe could exceed $150 billion annually over the coming decade.

Insilico Medicine and Bora Pharmaceuticals announce $2.5 billion collaboration (https://insilico.com/news/xa31uheux1-insilico-medicine-and-bora-pharmaceutica) 

Insilico Medicine continues to demonstrate that AI drug discovery is becoming commercially credible, announcing a major collaboration with Bora Pharmaceuticals valued at up to $2.5 billion. The partnership combines Insilico's AI-driven molecule generation platform with Bora's pharmaceutical development and manufacturing capabilities, illustrating how AI companies are increasingly moving beyond software into full drug development partnerships. 

Eli Lilly acquires AtaiBeckley for up to $3.8 billion (https://lilly.gcs-web.com/news-releases/news-release-details/lilly-acquire-ataibeckley-advance-therapies-treatment-resistant) 

Eli Lilly announced it will acquire AtaiBeckley, a clinical-stage biotechnology company developing psychedelic-inspired therapies for mental health disorders, in a deal worth $2.8 billion upfront with up to $1 billion in additional milestone payments, bringing the total potential value to $3.8 billion. At the center of the acquisition is BPL-003, an intranasal formulation of synthetic 5-MeO-DMT being developed for treatment-resistant depression, along with a broader pipeline of rapid-acting neuroplastogens. This marks Lilly's first major move into the rapidly emerging psychedelic medicine space and reflects growing confidence that these compounds could become the next generation of treatments for depression and other psychiatric disorders. More broadly, the acquisition signals that neuroscience—and particularly novel mental health therapeutics—is once again becoming a strategic priority for large pharmaceutical companies after years of relatively limited innovation.

Sanofi and Eli Lilly invest in Advancell for $315 million (https://firstwordpharma.com/story/7703295)

Sanofi and Eli Lilly jointly participated in a $315 million financing round for Australian radiopharmaceutical company Advancell. Radiopharmaceuticals represent one of oncology's fastest-growing sectors, combining radioactive isotopes with targeted delivery systems to selectively destroy cancer cells. The participation of two global pharmaceutical leaders signals growing confidence that targeted radiotherapy may become another pillar of precision oncology.

Genentech acquires Astex assets from Otsuka for approx. $515 million (https://allsci.com/news/licensing-deals/otsukas-astex-strikes-usd-515m-breast-cancer-deal-with-genentech-on-fbdd-platform/)

Genentech announced a deal with Otsuka's Astex unit valued at approximately $515 million, adding another precision oncology asset to Roche's already formidable cancer portfolio. Roche continues to strengthen its position in targeted therapies by selectively acquiring promising early-stage technologies rather than relying exclusively on internal discovery.

Johnson & Johnson acquires Sail Biomedicines for $2.58 billion (https://pharmaphorum.com/news/jj-takes-258bn-option-buy-vivo-car-t-firm-sail)

Johnson & Johnson agreed to acquire Sail Biomedicines in a transaction worth approximately $2.58 billion, expanding its capabilities in RNA-based therapeutics and advanced genetic medicines. As RNA technologies continue evolving beyond mRNA vaccines into gene regulation and precision medicine, large pharmaceutical companies are racing to establish expertise across multiple RNA modalities.

argenx acquires rights to Forte Therapeutics for $2.2 billion (https://www.fiercebiotech.com/biotech/argenx-acquires-forte-22b-get-hands-phase-2-stage-vitiligo-drug) 

argenx announced a multibillion-dollar transaction involving Forte Therapeutics, further expanding its immunology pipeline beyond the tremendous success of Vyvgart. The deal reflects argenx's broader ambition to become one of the leading independent immunology companies globally as autoimmune medicine continues attracting enormous investment.

📈 Capital Markets

BridgeBio raises over $1 billion (https://investor.bridgebio.com/news/news-details/2026/BridgeBio-Raises-1-Billion-in-Preferred-Equity-to-Accelerate-Present-and-Upcoming-Launches/default.aspx) 

BridgeBio completed a financing exceeding $1 billion, one of the largest biotech capital raises of the year. Rather than funding a single drug, the financing supports a broad portfolio spanning rare genetic diseases, cardiovascular medicine, and precision therapeutics. Investors continue rewarding companies with diversified pipelines and multiple potential value-creating catalysts.

Apnimed prices a $192 million IPO (https://news.vrtx.com/news-releases/news-release-details/vertex-acquire-crinetics-pharmaceuticals)

Sleep medicine company Apnimed successfully completed a $192 million IPO, providing funding to advance its novel oral therapy for obstructive sleep apnea. Today, most sleep apnea patients rely on CPAP machines, which suffer from poor long-term adherence. Apnimed hopes oral pharmacologic therapy could dramatically expand treatment options and potentially transform one of sleep medicine's largest unmet needs.

Scribe Therapeutics completes IPO with close to $129 million raise (https://www.biopharmadive.com/news/scribe-ipo-price-gene-editing-biotech-pcsk9-lpa/825933/) 

Scribe Therapeutics, the gene-editing company co-founded by Nobel laureate Jennifer Doudna, completed an upsized IPO. The company is developing next-generation CRISPR technologies designed to improve the precision, safety, and delivery of gene editing, with strategic backing from Sanofi through a concurrent private investment. The successful IPO signals renewed investor confidence in differentiated CRISPR platforms as the field enters its next phase of innovation.

⚖️ Legal, Policy & Regulation

FTC sues Hims & Hers (https://www.cnbc.com/2026/07/29/hims-and-hers-ftc-lawsuit-stock.html)

The Federal Trade Commission filed suit against Hims & Hers, alleging deceptive marketing practices surrounding compounded GLP-1 weight-loss medications. The case underscores increasing regulatory scrutiny of direct-to-consumer telehealth companies as demand for obesity treatments continues to surge. The broader question extends beyond one company: how should rapidly growing digital healthcare platforms balance aggressive marketing with patient safety and transparent communication?

Novo Nordisk sues Eli Lilly (https://www.cnbc.com/2026/07/21/novo-nordisk-sues-eli-lilly-glp-1-ads.html)

Novo Nordisk and Eli Lilly continue their increasingly public legal battle over obesity therapies, with Novo filing additional legal claims involving competitive marketing and related issues. As GLP-1 medicines become one of the largest pharmaceutical markets in history, competition between the industry's two dominant players is expanding beyond scientific innovation into advertising, intellectual property, manufacturing, and legal strategy.

House advances legislation supporting continued animal testing requirements (https://www.fiercebiotech.com/cro/us-house-passes-bill-direct-fda-update-clinical-trial-regulations-and-allow-non-animal-testing)

The U.S. House passed legislation reinforcing the continued role of animal testing in biomedical research while recognizing the importance of developing New Approach Methodologies, or NAMs. The debate has intensified as AI models, organoids, and organ-on-chip technologies improve. Most scientists agree these emerging tools should increasingly supplement—and eventually replace—certain animal studies where validated. However, many researchers argue that eliminating animal testing before robust alternatives are fully proven could create new safety risks during drug development.

With that, that is a wrap for July 2026 news.

This has been Petri Dish Perspectives. I’m Manead. I’ll be back next month with a recap for August. Thanks for listening. Goodbye!

© 2026 The Perspective Bureau LLC. All rights reserved.